Fig. 4.

Effect of IFNAR on nGD progression and on down-stream signaling pathways. a Body weight of Ifnar ^+/− (n = 12) and Ifnar ^−/− (n = 19) mice treated with CBE (37.5 mg/kg per day) from 8 days of age or untreated mice (control, n = 9). Results are means ± s.e.m. b Kaplan-Meyer survival curves for Ifnar ^+/− (n = 12) and Ifnar ^−/− (n = 19) mice. c qPCR analysis of various genes in cortical homogenates from ~30-day-old Ifnar ^+/− (n = 2) and Ifnar ^−/− (n = 3) mice treated with CBE (37.5 mg/kg per day) from 8 days of age. Results are expressed as fold change of CBE-treated versus control and are means ± s.e.m. CT values were normalized to levels of HPRT. *p < 0.005, **p < 0.001. d Left, Western blots of homogenates (80 μg of protein) from cortex of ~30-day-old Ifnar ^+/− (+/−) and Ifnar ^−/− (−/−) (control) mice treated with or without CBE (+/− CBE, −/− CBE) from 8 days of age. Blots were probed with an anti-MAC2 antibody. Results are representative of three experiments for control mice and five for CBE treated mice. GAPDH was used as loading control. Right Densitometer analysis of the blots. *p < 0.05